First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.

Cescon, David W.; Traina, Tiffany A.; Schmid, Peter; Cortes, Javier; Shao, Zhimin; Saji, Shigehira; Jung, Kyung Hae; Bachelot, Thomas; Wang, Shouman; Ramirez, Emilio Murillo; Basaran, Gul; Chae, Yee Soo; Stradella, Agostina; Mathiba, Rofhiwa; Chen, Shin-Cheh; Battelli, Nicola; Niikura, Naoki; Zhao, Kechen; Maxwell, Micah J.; Dent, Rebecca Alexandra

doi:10.1200/JCO.2026.44.16_suppl.1002

First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.

Date

2026

Authors

Ramirez, Emilio Murillo

dc.identifier.issn

0732-183X
1527-7755

dc.identifier.doi

10.1200/JCO.2026.44.16_suppl.1002

dc.description.volume

44

dc.description.issue

16_SUPPL

Publisher

LIPPINCOTT WILLIAMS & WILKINS

DOI

10.1200/JCO.2026.44.16_suppl.1002
10.1200/JCO.2026.44.16_suppl.1002

Keywords

Oncology

URI

https://doi.org/10.1200/JCO.2026.44.16_suppl.1002
https://openaccess.acibadem.edu.tr/handle/11443/11582

Collections

WOS

Full item page

First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.

Date

Authors

Journal Title

Journal ISSN

Volume Title

dc.identifier.issn

dc.identifier.doi

dc.identifier.other

dc.description.volume

dc.description.issue

Publisher

DOI

Abstract

Description

Keywords

Citation

URI

Collections

Endorsement

Review

Supplemented By

Referenced By